Spotlight on Market Access

Pharma Industry Can Help With Employer Challenges in Covering Specialty Drugs

As more high-cost drugs, including one-time gene therapies, come onto the market, employers are considering implementing a variety of contracting models to make sure their employees have access to these agents. However, even as innovative new approaches are being explored, employers have experienced challenges in executing them. Manufacturers can ensure their products are being covered when they understand employers’ concerns and help address those issues, suggest industry experts.

0 Comments
© 2024 MMIT

Magellan Rx/Trapelo Precision Oncology Solution Aims to Improve Patient Outcomes

With more and more oncolytics targeting specific alterations in tumors, the area of precision oncology is developing rapidly. To help bring some insight into this market, Magellan Rx Management, a division of Magellan Health, Inc., and Trapelo Health, a wholly owned subsidiary of NeoGenomics Bioinformatics, recently unveiled a collaboration aimed at helping both providers and payers navigate this complex space and ultimately improve patient outcomes.

0 Comments
© 2024 MMIT

Moody’s Is Bullish on Pharma Industry for Next 18 Months

The pharmaceutical industry should continue to enjoy strong financial results in the next 12 to 18 months, according to a new report from Moody’s Investors Service. The credit ratings firm projects 4% to 6% growth in annual earnings before interest, taxes, depreciation and amortization over that period.

0 Comments
© 2024 MMIT

Many Large Employers Want Government to Help Control Health Care Costs

The majority of large private employers say that health benefit costs are excessive and a greater government role in providing health care coverage and containing costs would benefit their business and employees, according to a recent survey by the Purchaser Business Group on Health and the Kaiser Family Foundation. Based on the responses from key decision-makers at 302 large private employers with at least 5,000 employees, the survey found that 87% of respondents believed the cost of providing health benefits will become unsustainable in the next five to 10 years. Meanwhile, the majority of respondents said they were likely to implement cost-control practices, such as value-based benefit designs and use of an individual coverage health reimbursement arrangement (ICHRA).

0 Comments
© 2024 MMIT

FDA Approval of Biogen’s Alzheimer’s Drug Stirs Up Heated Debate, Cost Questions

The FDA on June 7 delivered its much-anticipated approval of Biogen Inc.’s Aduhelm (aducanumab-avwa), immediately stirring up a furor over its high cost, reigniting doubts about its effectiveness, and spurring speculation about how public and private payers will approach coverage for the first novel treatment approved for Alzheimer’s disease since 2003.

0 Comments
© 2024 MMIT

Fee Scheduler Aids in Medical Benefit Drug Reimbursement

MMIT has launched its new Fee Scheduler solution. The product provides a simplified, self-serve workflow for payers to select appropriate pricing methodologies to reimburse medically covered pharmaceuticals. The product will replace payers’ manual processes today across dozens of fee schedules to free up internal resources, streamline the flow of fee schedules to third party vendors and provide clients with the ability to establish custom class pricing to handle biosimilars and other exceptions — all backed by RJ Health data.

0 Comments
© 2024 MMIT

Current Market Access to Alzheimer’s Disease Medications

The FDA on June 7 approved Biogen Inc.’s Aduhelm (aducanumab) to treat Alzheimer’s disease, the first novel therapy approved in this indication since 2003. The accelerated approval of Aduhelm was controversial as results of two Phase III trials in patients with early-stage and mild Alzheimer’s contradicted each other. There are a host of other Alzheimer’s medications on the market, all of which are covered under the pharmacy benefit. The majority of insured people under commercial and Medicaid formularies have plans that put Alzheimer’s drugs under the preferred/preferred (prior authorization and/or step therapy) tier and covered/covered (PA/ST) tiers. More than half of payer pharmacy benefit formularies do not require step therapy or prior authorization for Alzheimer’s medications.

0 Comments
© 2024 MMIT

OEP Winners Credit Year-Round Marketing, Outreach

Medicare Advantage enrollment grew just 1% during the 2021 Open Enrollment Period (OEP) that ran from January to March, compared with growth of 7% during the preceding Annual Election Period (AEP), according to AIS’s Directory of Health Plans (DHP). While the large MA insurers continued to nab the bulk of OEP signups (see infographic, p. 7), an AIS Health analysis finds that of the top 25 OEP performers, regional players followed their AEP successes with OEP gains that were impressive relative to their size.

0 Comments
© 2024 MMIT

Top Payers Jockey Behind UnitedHealthcare in 2021 Medicare Open Enrollment Period

Medicare Advantage enrollment grew by about 257,000 lives during the 2021 Open Enrollment Period (OEP), according to CMS’s May data release and AIS’s Directory of Health Plans. As in the Annual Election Period (AEP), UnitedHealthcare dominated, holding about 32% of the overall OEP gains. Still, there were some shakeups among the other largest MA payers. In terms of membership gains, Centene Corp. (including enrollment from its WellCare brands) jumped from the No. 4 spot in the AEP to the No. 2 spot in the OEP, while Kaiser Permanente rose from No. 7 to No. 5. Cigna Corp., meanwhile, lost much of its momentum from the AEP, dropping from No. 9 to No. 20. See the top 25 OEP performers in the chart below.

0 Comments
© 2024 MMIT

Zeposia May Have Challenges Within Ulcerative Colitis Class

A new entrant to the ulcerative colitis therapeutic class brings a new mechanism of action. However, according to payers responding to a survey by Zitter Insights, the treatment, Bristol Myers Squibb’s Zeposia (ozanimod), may have some challenges breaking into the space.

On May 27, the FDA gave an additional indication to Zeposia for the treatment of adults with moderately to severely active ulcerative colitis. It is the first and only sphingosine 1-phosphate (S1P) receptor modulator approved for this indication. The agency initially approved the capsule on March 26, 2020, for relapsing forms of multiple sclerosis (MS). Three other oral S1Ps are approved for MS: Gilenya (fingolimod) and Mayzent (siponimod), both from Novartis Pharmaceuticals Corp., and new entrant Ponvory (ponesimod), from the Janssen Pharmaceutical Companies of Johnson & Johnson.

0 Comments
© 2024 MMIT